Health & Biotech Copy RSS link Link copied to clipboard!
GSK and AstraZeneca shares fall despite strong cancer drug sales
Pharmaceutical giants GSK and AstraZeneca reported better-than-forecast first quarter profits driven by strong cancer treatment sales. AstraZeneca saw a 12% rise in operating profits, while GSK achieved a 9% earnings increase. However, shares in both companies fell by 4% and 2% respectively. The decline occurred despite solid revenue growth, as both firms held off from upgrading their full-year earnings outlook amid an uncertain economic backdrop, leaving investors feeling short-changed.
Precision fermentation reshapes nutraceutical ingredient supply chains
Precision fermentation is transforming the nutraceutical industry by enabling consistent, scalable production of vitamins, amino acids, and bioactives independent of agricultural variability. Driven by climate volatility, geopolitical instability, and sustainability demands, this technology decouples production from traditional farming. Key developments include FDA confirmation of NMN legality in September 2025 and the shift to yeast-based astaxanthin. The global market is projected to grow from $5.8 billion in 2025 to over $151 billion by 2034, with contract development and manufacturing organizations (CDMOs) playing a central role in scaling these innovations.
Chiesi acquires KalVista Pharmaceuticals for $1.9bn to expand rare disease portfolio
Chiesi Group announced on 29 April 2026 a definitive agreement to acquire KalVista Pharmaceuticals for approximately $1.9bn. The cash deal, valued at $27.00 per share, is expected to close in Q3 2026. The acquisition brings EKTERLY (sebetralstat), an oral therapy for hereditary angioedema, into Chiesi's portfolio. This transaction represents Chiesi's largest acquisition to date and aims to strengthen its rare disease capabilities, particularly in the United States and global markets.
LTR Pharma advances SPONTAN intranasal therapy with US expansion strategy
LTR Pharma (ASX:LTP) reported encouraging interim Phase II data for its SPONTAN intranasal therapy, demonstrating faster absorption than oral alternatives with no serious adverse events. The company outlined a dual US regulatory pathway combining streamlined approval and personalised medicine access. Backed by strong funding and no debt, LTR Pharma aims to complete supporting studies and advance toward broader regulatory approval, leveraging early Australian real-world validation.
Saudi Arabia develops as Middle East hub for clinical trials
Saudi Arabia is emerging as a key Middle East hub for clinical trials driven by state investment under Vision 2030 and rapid healthcare expansion. The Kingdom offers a large patient base, modern infrastructure, and a growing public-private ecosystem. Logistics provider Oximio has opened a dedicated facility to support temperature-controlled supply chains. While challenges like logistics costs and patient awareness remain, the country is becoming a strategic location for sponsors targeting chronic diseases.
FDA publicly identifies over 7,700 noncompliant companies regarding drug amount reporting
On March 31, 2026, the US Food and Drug Administration (FDA) published a list identifying over 7,700 companies that failed to submit required annual drug amount reports for calendar year 2024. The data includes 1,254 companies with active drug listings and 6,480 with inactive listings. This requirement, mandated by the CARES Act, aims to improve FDA oversight of the drug supply chain and prevent shortages. Non-compliance exposes registrants to regulatory risk and undermines the agency's ability to monitor supply stability.
Parexel acquires Vitrana to integrate AI-enabled pharmacovigilance platform
Parexel has acquired Vitrana, a provider of an AI-enabled, end-to-end pharmacovigilance technology platform. The acquisition enables Parexel to offer a fully integrated model combining PV technology and services, addressing increasing regulatory volume and data complexity. Vitrana will operate as 'Vitrana – a Parexel Company' within Parexel's Patient Safety Services organization. The system-agnostic platform aims to improve accuracy, cycle times, and EDC-to-safety integration while allowing human experts to focus on complex analysis. This move completes Parexel's AI-enabled suite spanning the entire development lifecycle.
Eli Lilly lifts 2026 revenue guidance as Q1 marks dominant opening
Eli Lilly reported Q1 2026 revenue of $19.8bn, a 56% increase year-on-year, driven by strong sales of Mounjaro ($8.7bn) and Zepbound ($4.2bn). The company raised its full-year 2026 revenue guidance to $82bn-$85bn. Growth was also supported by the early rollout of oral GLP-1RA Foundayo. CEO Dave Ricks confirmed continued M&A activity, including a $2.3bn acquisition of Ajax Therapeutics.
Eli Lilly stock rises 4.44% on strong Q1 2026 earnings and FDA regulatory update
Eli Lilly and Co stock rose 4.44% on May 1 following first-quarter 2026 earnings that exceeded market expectations, driven by growth in cardiometabolic products Mounjaro and Zepbound. Management raised full-year 2026 revenue and EPS guidance. The US FDA proposed excluding tirzepatide from a compounding list, protecting market share. Analysts upgraded ratings and price targets, reinforcing positive sentiment.
AmpleLogic launches AI-powered Annual Product Quality Review software
AmpleLogic has introduced new Annual Product Quality Review (APQR) software designed to automate pharmaceutical quality compliance using artificial intelligence. The platform integrates with existing LIMS, eQMS, MES, and ERP systems to eliminate data silos and reduce report generation time from weeks to minutes. By leveraging OCR and predictive analytics, the solution enables real-time oversight and proactive risk management, helping companies meet regulatory standards from the FDA, EMA, and WHO. The software supports tailored workflows, electronic signatures compliant with 21 CFR Part 11, and automated trend analysis to ensure continuous quality improvement.
Bambusa completes enrolment in BBT001 Phase Ib/IIa trial for atopic dermatitis
Bambusa Therapeutics has completed patient enrolment in its Phase Ib/IIa trial evaluating BBT001 for moderate-to-severe atopic dermatitis. The randomised, double-blind, placebo-controlled study is conducted at sites in New Zealand and the US. Primary endpoints include safety and tolerability, with exploratory efficacy assessments planned. Top-line results are expected by mid-2026. BBT001 remains investigational with no approvals to date.
FDA approves Auvelity for Alzheimer's disease agitation
The US Food and Drug Administration has approved Auvelity, a non-antipsychotic oral medication, for treating agitation associated with dementia due to Alzheimer's disease. Manufactured by Axsome Therapeutics, the drug combines dextromethorphan and bupropion. Approval is based on phase 3 trials showing efficacy in delaying relapse and reducing agitation severity, though one acute treatment trial did not meet its primary endpoint. The approval adds a new option for managing neuropsychiatric symptoms in Alzheimer's patients.
AstraZeneca shares drop after US regulatory panel votes against breast cancer drug
AstraZeneca shares fell nearly 2% after the US FDA's Oncologic Drugs Advisory Committee voted six to three against recommending camizestrant, an experimental treatment for breast cancer. The panel cited concerns regarding trial design rather than safety or efficacy. While the drugmaker expressed disappointment, analysts suggest approval remains possible through other studies. The setback is viewed as minor relative to the company's broader growth targets.
Sulfated bile acid from human gut commensal alleviates paediatric sepsis in mice
Researchers identified a sulfated bile acid produced by a human gut commensal bacterium that alleviates paediatric sepsis in mouse models. The study highlights the therapeutic potential of specific microbial metabolites in treating severe inflammatory conditions in children, demonstrating a protective effect against sepsis-induced pathology.
NHS England explores at-home diagnostic testing through NHS App
NHS England is exploring a national home-testing service via the NHS App as part of its HomeTest Programme. The organisation launched a market engagement exercise on 20 April 2026 to assess supplier capability for clinically validated tests in areas such as sexual health and primary care. The programme aims to establish a trusted national capability by 2027/28, subject to feasibility recommendations and ministerial sign-off. Concerns regarding clinical oversight and result interpretation remain.
Bristol Myers Squibb reports modest Q1 growth amid late-stage pipeline buzz
Bristol Myers Squibb reported first-quarter revenues of $11.5bn, a 1% increase year-on-year, with non-GAAP EPS of $1.58, beating analyst forecasts. While Eliquis remains a top earner, the company faces patent expiry risks. Investors are focused on late-stage readouts for milvexian, a potential Eliquis successor, and Cobenfy in Alzheimer's psychosis. BMS reaffirmed 2026 revenue guidance between $46bn and $47.5bn.
EnteroBiotix secures £19m to advance IBS treatment
EnteroBiotix has secured £19 million in financing to advance EBX-102-02, a microbiome therapeutic, into Phase IIb development for irritable bowel syndrome with constipation. The company will conduct a randomised, double-blind, placebo-controlled trial enrolling approximately 300 patients across sites in the UK. First patient dosing is expected in Q2 2026, with topline efficacy data anticipated in H2 2027. The trial aims to confirm earlier efficacy signals and position the drug as a potential first disease-modifying therapy for the condition.
AstraZeneca confirms £300m UK investment commitment
AstraZeneca has confirmed a £300m investment in the UK, reversing a previous decision to halt major projects. The commitment, announced by Prime Minister Keir Starmer in Parliament, involves resuming a £200m expansion at the Cambridge campus and allocating £100m to the Macclesfield facility for a new laboratory. The move follows a bilateral pricing agreement with the United States intended to future-proof jobs and improve the NHS medicines environment. The company currently employs around 10,000 people in the UK.
Incheon, South Korea: Researchers review single-vesicle tools for earlier cancer diagnosis and personalized medicine
- Researchers at Incheon National University and the University of Pennsylvania reviewed technologies for analyzing extracellular vesicles individually to overcome limitations of bulk testing methods.
- The study highlights potential for detecting rare disease-linked vesicles with high precision for earlier diagnosis of pancreatic cancer, cholangiocarcinoma, and lung adenocarcinoma.
- Advanced methods combining microfluidics, sequencing, and signal amplification could enable routine liquid biopsies for monitoring cardiovascular and neurodegenerative disorders.
- Future developments may integrate artificial intelligence to interpret vast datasets from platforms analyzing up to one million vesicles per test.
- The review suggests single-EV profiling could move from specialized laboratories into mainstream healthcare within the next decade for personalized treatment decisions.
Sanofi secures EU recommendation for tolebrutinib in multiple sclerosis
Sanofi received a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use for tolebrutinib, a treatment for secondary progressive multiple sclerosis. The drug showed a 31 per cent reduction in disability progression and a 38 per cent decrease in new brain lesions compared with placebo. This decision follows a rejection by US regulators in December due to safety and efficacy concerns. If approved, the drug will be marketed in Europe as Cenrifki.